Robbie Marcus
Stock Analyst at JP Morgan
(0.61)
# 1996
Out of 5,218 analysts
144
Total ratings
53.41%
Success rate
6.70%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Insulet | Maintains: Overweight | 280 330 | 269.59 | 22.41% | 4 | Dec 12, 2024 | |
CeriBell | Initiates Coverage On: Overweight | 32 | 29.33 | 9.1% | 1 | Nov 5, 2024 | |
Stryker | Maintains: Overweight | 375 420 | 375.05 | 11.99% | 6 | Oct 30, 2024 | |
AtriCure | Maintains: Overweight | 30 40 | 31.49 | 27.02% | 5 | Oct 30, 2024 | |
Edwards Lifesciences | Maintains: Neutral | 72 78 | 73.33 | 6.37% | 4 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 75 85 | 77.21 | 10.09% | 2 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 495 575 | 539.38 | 6.6% | 4 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 125 120 | 106.86 | 12.3% | 4 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 90 | 80.98 | 11.14% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 53 50 | 46.2 | 8.23% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 44 42 | 30.37 | 38.29% | 12 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | n/a | n/a | n/a | 5 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 82 85 | 90.16 | -5.72% | 8 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 15 8 | 7.51 | 6.52% | 2 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 19 21 | n/a | n/a | 3 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 36 13 | 12.81 | 1.48% | 5 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 115 75 | 72.53 | 3.41% | 5 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 100 120 | 94.91 | 26.44% | 3 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 9 17 | 11.01 | 54.41% | 3 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 40 62 | 37.21 | 66.62% | 3 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 284 250 | 246.11 | 1.58% | 9 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 10 16 | 13.75 | 16.36% | 3 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 8 7 | 8.94 | -21.7% | 11 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 340 181 | 188.34 | -3.9% | 4 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | 56 43 | 24.06 | 78.72% | 5 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 15 17 | 18.59 | -8.55% | 2 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | n/a | n/a | n/a | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 125 118 | 113.45 | 4.01% | 5 | Oct 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | n/a | n/a | n/a | 2 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 116 156 | 86.54 | 80.26% | 2 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 130 105 | 82.47 | 27.32% | 6 | Dec 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | n/a | n/a | n/a | 2 | Nov 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | 220 | n/a | n/a | 2 | Sep 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | 10 6 | n/a | n/a | 5 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 55 40 | 139.11 | -71.25% | 2 | May 5, 2020 |